LifeStance Health Group, Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

LifeStance is one of the nation’s largest providers of virtual and in-person outpatient mental health care. At the time of its IPO, the Company operated 370 centers and employed 3,300 psychiatrists, advanced practice nurses, psychologists, and therapists across 27 states. The Company provides virtual and in-person outpatient mental health care for children, adolescents, and adults experiencing a variety of mental health conditions including depression, anxiety disorder, schizophrenia, and post-traumatic stress disorder.

Due to Covid lockdowns, total patient visits increased from 1,353,285 in 2019 to 2,290,728 in 2020. Meanwhile, the Company’s total revenue grew from $212.5 million in 2019 to $377.2 million in 2020 on a pro forma basis.

The approval and introduction of Covid vaccines beginning in December 2021 increased demand for in-person services and fewer patients would be seeking virtual care. In-patient services are also inherently more expensive as they require office space, etc. Many physicians were also burned out at this point and were resigning, resulting in a shortage and a need for new physicians to be hired and trained, increasing costs.

On February 16, 2021, LifeStance filed a Registration Statement on Form S-1, which, after several amendments made pursuant to comments from the SEC, would later be utilized for the IPO. Initially, the defendants stated they intended to sell a total of 40 million shares at a price range of between $15.00 and $17.00 per share, however, based on the defendants’ strong marketing efforts to sell the IPO, they were able to price the shares sold in the IPO at $18.00 per share and to sell 46 million shares in the IPO. In the Registration Statement, the Company highlighted its aforementioned growth numbers while claiming it currently had exciting growth opportunities on its horizon. It then claimed that Covid had had no material impact on its business, instead pointing to decreased stigmatization of mental health, though it allowed that the pandemic had shown a “spotlight” on mental health that would cause its business to continue to increase.

On August 11, 2021, less than two months after the IPO, LifeStance announced its second quarter 2021 (“2Q21”) financial results for the period ended June 30, 2021 disclosing a net loss of $70 million, compared to net loss of just $27.6 million for the period from April 1, 2020 to May 14, 2020 (Predecessor) and $4.3 million for the period from April 13, 2020 to June 30, 2020 (Successor). The company also now disclosed a decrease in its clinician retention levels.

On November 8, 2021, the Company reported its third quarter 2021 results, announcing that its clinician retention had “stabilized” at around 80%. Defendants reported LifeStance’s fiscal 2021 results on March 10, 2022, and during a conference call with investors admitted that a recent Stanford study had shown that 75% of patients prefer in-person treatment. It also said that it would be reducing its number of brick and mortar facilities that it was planning on building to increase profitability.

LifeStance common stock currently trades at $8.11 per share, over 50% below the IPO price of $18.00 per share.